RESUMO
In low- and middle-income countries (LMIC), growth impairment is common; however, the trajectory of growth over the course of the first month has not been well characterised. To describe newborn growth trajectory and predictors of growth impairment, we assessed growth frequently over the first 30 days among infants born ≥2000 g in Guinea-Bissau, Nepal, Pakistan and Uganda. In this cohort of 741 infants, the mean birth weight was 3036 ± 424 g. For 721 (98%) infants, weight loss occurred for a median of 2 days (interquartile range, 1-4) following birth until weight nadir was reached 5.9 ± 4.3% below birth weight. At 30 days of age, the mean weight was 3934 ± 592 g. The prevalence of being underweight at 30 days ranged from 5% in Uganda to 31% in Pakistan. Of those underweight at 30 days of age, 56 (59%) had not been low birth weight (LBW), and 48 (50%) had reached weight nadir subsequent to 4 days of age. Male sex (relative risk [RR] 2.73 [1.58, 3.57]), LBW (RR 6.41 [4.67, 8.81]), maternal primiparity (1.74 [1.20, 2.51]) and reaching weight nadir subsequent to 4 days of age (RR 5.03 [3.46, 7.31]) were highly predictive of being underweight at 30 days of age. In this LMIC cohort, country of birth, male sex, LBW and maternal primiparity increased the risk of impaired growth, as did the modifiable factor of delayed initiation of growth. Interventions tailored to infants with modifiable risk factors could reduce the burden of growth impairment in LMIC.
Assuntos
Magreza , Peso ao Nascer , Feminino , Guiné-Bissau/epidemiologia , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Nepal/epidemiologia , Paquistão/epidemiologia , Magreza/epidemiologia , Uganda/epidemiologiaRESUMO
OBJECTIVE: To update the estimated global incidence of Japanese encephalitis (JE) using recent data for the purpose of guiding prevention and control efforts. METHODS: Thirty-two areas endemic for JE in 24 Asian and Western Pacific countries were sorted into 10 incidence groups on the basis of published data and expert opinion. Population-based surveillance studies using laboratory-confirmed cases were sought for each incidence group by a computerized search of the scientific literature. When no eligible studies existed for a particular incidence group, incidence data were extrapolated from related groups. FINDINGS: A total of 12 eligible studies representing 7 of 10 incidence groups in 24 JE-endemic countries were identified. Approximately 67,900 JE cases typically occur annually (overall incidence: 1.8 per 100,000), of which only about 10% are reported to the World Health Organization. Approximately 33,900 (50%) of these cases occur in China (excluding Taiwan) and approximately 51,000 (75%) occur in children aged 0-14 years (incidence: 5.4 per 100,000). Approximately 55,000 (81%) cases occur in areas with well established or developing JE vaccination programmes, while approximately 12,900 (19%) occur in areas with minimal or no JE vaccination programmes. CONCLUSION: Recent data allowed us to refine the estimate of the global incidence of JE, which remains substantial despite improvements in vaccination coverage. More and better incidence studies in selected countries, particularly China and India, are needed to further refine these estimates.
Assuntos
Surtos de Doenças/estatística & dados numéricos , Encefalite Japonesa/epidemiologia , Saúde Global/estatística & dados numéricos , Adolescente , Fatores Etários , Criança , Proteção da Criança , Pré-Escolar , Surtos de Doenças/prevenção & controle , Encefalite Japonesa/prevenção & controle , Feminino , Saúde Global/tendências , Humanos , Incidência , Lactente , Recém-Nascido , Vacinas contra Encefalite Japonesa , Masculino , Pediatria , Vigilância da População , Medição de Risco , Organização Mundial da SaúdeAssuntos
Betacoronavirus , Saúde da Criança , Infecções por Coronavirus/prevenção & controle , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Pobreza , COVID-19 , Criança , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/transmissão , Países em Desenvolvimento , Saúde Global , Humanos , Pneumonia Viral/diagnóstico , Pneumonia Viral/transmissão , Fatores de Risco , SARS-CoV-2Assuntos
Saúde Global , Pneumonia Bacteriana/mortalidade , Pneumonia Bacteriana/prevenção & controle , Antibacterianos/uso terapêutico , Criança , Pré-Escolar , Conservação dos Recursos Naturais , Feminino , Humanos , Masculino , Pneumonia Bacteriana/terapia , Prevenção Primária/organização & administração , Medição de Risco , Vacinação/estatística & dados numéricos , Organização Mundial da SaúdeRESUMO
Bacillus cereus is increasingly being acknowledged as a serious bacterial pathogen in immunosuppressed hosts. We report a case of fatal B. cereus sepsis in a patient with newly diagnosed acute leukemia following resolving neutropenic enterocolitis. Gastrointestinal complaints are common during induction chemotherapy, yet some antimicrobial coverage suitable for generalized neutropenia is not optimal for the eradication of B. cereus. This case demonstrates that, in the neutropenic patient with gastrointestinal complaints or in the setting of resolving neutropenic enterocolitis, it is important to anticipate possible B. cereus infection and sepsis.